Introduction
============

Heart failure (HF) can result from cardiac overload or injury as well as from a complex interplay of genetic, neurohormonal, and inflammatory factors. HF is classified as being associated with a reduced ejection fraction (HFREF) or with a normal ejection fraction (HFNEF). The percentages of patients and the mortality rates are similar in patients with HFREF and HFNEF.^[@b1]--[@b2]^ The likelihood of survival is higher in patients with HFREF than in those with HFNEF, and the survival rate in HFNEF has not significantly improved in recent years.^[@b3]^ Various biomarkers, including those for inflammation and neurohormones, provide important information about the pathogenesis, risk stratification, and diagnosis of HF and are used to monitor response to therapy.^[@b4]^ Inflammatory markers are closely associated with pathogenesis, poor functional state, and adverse prognosis in patients with HF.

Pentraxin 3 (PTX3) is a newly identified member of the pentraxin superfamily, which includes C‐reactive protein (CRP) and serum amyloid P. In contrast to CRP, which is produced by the liver, PTX3 is produced by various cell types in various tissues, especially in the vasculature, in response to inflammatory stimuli.^[@b5]^ PTX3 may reflect local inflammatory status in tissues and thus may be a new biomarker of inflammation.^[@b6]^ We recently demonstrated that plasma levels of PTX3, but not high‐sensitivity CRP (hs‐CRP), were significantly higher in patients with HFNEF than in non‐HF patients.^[@b7]^ In addition, these elevated levels of PTX3 were significantly and independently correlated with the presence of HFNEF in patients with normal left ventricular ejection fraction (LVEF).^[@b7]^ Other studies have also shown that PTX3 is a predictor of adverse clinical outcome in patients with HFREF.^[@b8]--[@b9]^ Consequently, PTX3 may be a useful inflammatory marker in cardiovascular medicine.

Although much attention has been focused on HFREF, less is known regarding factors that correlate with clinical outcome in patients with HFNEF. The Irbesartan in Heart Failure With Preserved Ejection Fraction (I‐PRESERVE) study demonstrated that age, presence of diabetes mellitus, history of hospitalization for HF, New York Heart Association classification, N‐terminal pro‐B‐type natriuretic peptide levels, and LVEF were associated with adverse outcomes in patients with HFNEF.^[@b10]^ The relationships between inflammatory markers and prognosis in HFNEF, however, remain unknown. This study was designed to determine the ability of plasma PTX3 levels to predict future cardiovascular events in patients with HFNEF.

Methods
=======

Patients and Protocol
---------------------

We initially screened 747 chronic HF patients under a clinically stable condition with New York Heart Association functional class II to IV who were referred to Kumamoto University Hospital, Kumamoto, Japan. We did not include decompensated HF patients with acute HF. The diagnosis of HF was based on the Framingham criteria for HF.^[@b11]^ None of the patients had any noncardiac causes of HF‐like symptoms, especially lung disease (eg, chronic obstructive lung disease). The diagnosis of HFNEF was based on the criteria formulated by the European Working Group on HFNEF.^[@b12]^ HFREF was defined as reduced systolic left ventricular (LV) function (LVEF≤50%). HFNEF was defined as normal or mildly abnormal systolic LV function (LVEF\>50%) with LV diastolic dysfunction. LV diastolic dysfunction for HFNEF was defined as (1) a ratio of mitral early diastolic peak flow velocity to tissue Doppler early mitral annular diastolic velocity (E/e') ≥15; (2) E/e' ≥8 and \<15 and B‐type natriuretic peptide (BNP) levels \>200 pg/mL; or (3) E/e' ≥8 and \<15 and LV mass index (LVMI) ≥122 g/m^2^ (females) or 149 g/m^2^ (males). Patients were excluded if they had active systemic inflammatory disease, chronic renal failure requiring hemodialysis, collagen disease, presence of malignancy, or acute coronary syndrome within 3 months preceding enrollment. Twenty‐three HF patients with normal LVEF who did not meet these criteria were excluded. The study finally enrolled 360 patients with HFNEF ([Figure 1](#fig01){ref-type="fig"}). The study complied with the Declaration of Helsinki regarding investigation in humans and was approved by the institutional review committee of each institution. The study was also conducted in accordance with the guidelines of the ethics committee of our institution. Written informed consent was obtained from all patients. This study was registered at the University Hospital Medical Information Network Clinical Trials Registry with the identification number UMIN000002170.

![Flow chart showing the protocol that was used for enrollment of HFNEF patients in the present study. BNP indicates B‐type natriuretic peptide; E/e', ratio of mitral early diastolic peak flow velocity to tissue Doppler early mitral annular diastolic velocity; HF, heart failure; HFNEF, HF with normal ejection fraction; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; NYHA, New York Heart Association.](jah3-3-e000928-g1){#fig01}

Measurement of Plasma PTX3 Levels and Other Blood Parameters
------------------------------------------------------------

Venous blood samples were obtained from patients under clinically stable and fasting conditions. Serum and plasma samples were kept frozen at −80°C until later tests. The estimated glomerular filtration rate was calculated using the Japanese Society of Nephrology formula.^[@b13]^ PTX3 levels were measured using a high‐sensitivity enzyme‐linked immunosorbent assay system (values ranged from 0.1 to 20 ng/mL; Perseus Proteomics). Other factors that were measured included serum hs‐CRP levels and plasma tumor necrosis factor‐α, interleukin‐6, and BNP levels.

Doppler Echocardiography
------------------------

Echocardiography was performed in standard parasternal and apical views by a specialized echocardiologist using commercially available ultrasound systems (Vivid 7, GE‐Vingmed Ultrasound; Aplio XG, Toshiba). LVEF was measured in biplane apical (2‐ and 4‐chamber) views using a modification of Simpson\'s method. The E/e' ratio is used as an index of LV filling pressure and abnormal LV relaxation.^[@b14]^ To assess LV diastolic function, E/e' was measured, as described previously,^[@b15]^ as was the medial annulus of E/e'. LV mass was calculated, as described previously,^[@b16]^ and the LVMI was expressed relative to body surface area.

Follow‐up
---------

Patients with HFNEF were followed prospectively at the outpatient clinic until December 2012 or until an endpoint occurred. The endpoint was a composite of cardiovascular death, nonfatal MI, unstable angina pectoris, nonfatal ischemic stroke, hospitalization for HF decompensation, or coronary revascularization. Cardiovascular events were ascertained from a review of medical records and confirmed by direct contact with the patients, their families, and physicians. Patients were divided into low‐ and high‐PTX3 groups based on the median concentration of PTX3 (3.0 ng/mL).

Definition of Cardiovascular Events
-----------------------------------

Cardiovascular death was defined as death because of MI (within 28 days), congestive heart failure, or documented sudden death without apparent noncardiovascular causes. MI was diagnosed as a rise or fall in cardiac biomarkers (plasma creatine kinase‐MB or cardiac troponin‐T) greater than the 99th percentile of the upper limit of normal, together with evidence of myocardial ischemia with at least one of the following: ECG changes (recent ST‐T changes, left bundle branch block, or a pathological Q wave) or imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.^[@b17]^ Unstable angina pectoris was diagnosed from new or accelerating symptoms of myocardial ischemia accompanied by recent ischemic ST‐T‐wave changes. Ischemic stroke was diagnosed by both neurological symptoms and radiological evidence, excluding intracranial hemorrhage. Hospitalization for HF decompensation was defined as admission for symptoms typical of HF with objective signs of worsening HF requiring intravenous drug administration. Coronary revascularization was defined as coronary artery bypass grafting or percutaneous coronary intervention in patients with stable angina pectoris. For subjects experiencing 2 or more cardiovascular events, only the first event was considered in the analysis.

Statistical Analysis
--------------------

Parameters with a normal distribution, as assessed by the Shapiro‐Wilk test, are expressed as mean±SD. Parameters with a skewed distribution, such as PTX3, hs‐CRP, tumor necrosis factor‐α, interleukin‐6, and BNP levels, as well as E/e' and LVMI, are shown as median values (interquartile range) and were logarithmically transformed before linear regression analysis. Differences between continuous variables were analyzed by the unpaired *t* test and the Mann‐Whitney *U* test, as appropriate. Differences between categorical variables were analyzed by the chi‐square test. Linear regression analysis was used to determine the associations between PTX3 and BNP levels, LVMI, inflammatory makers, and cardiovascular events. Survival data were analyzed by the Kaplan‐Meier method and assessed by the log‐rank test. Age‐ and sex‐adjusted event rates were calculated by multivariable logistic regression analyses. The ability of any marker to predict cardiovascular events was assessed by Cox proportional hazards regression analysis. In Cox proportional hazards regression analyses, associations between groups and all other parameters were first analyzed by univariate analysis followed by multivariable analysis after adjustment for factors that were significant with univariate analysis. Multivariable Cox proportional hazards regression analyses were also performed using forced inclusion models. Model 1 incorporated the inflammatory makers PTX3, hs‐CRP, tumor necrosis factor‐α, interleukin‐6, and BNP. Model 2 incorporated the 5 prognostic factors (PF5) that were identified during the I‐PRESERVE study^[@b10]^ in patients with HFNEF---age, presence of diabetes mellitus, previous hospitalization for HF, New York Heart Association classification, and LVEF---as well as BNP and PTX3. Model 3 incorporated PF5, BNP, and hs‐CRP. Model 4 incorporated PF5, BNP, hs‐CRP, and PTX3. Estimates of the C‐statistic for Cox proportional hazards regression models were calculated.^[@b18]--[@b20]^ C‐statistics were estimated after PTX3 and BNP levels were added to PF5.^[@b10]^ The proportional hazards assumption was confirmed by the Schoenfeld global test. Calibration of Cox regression models was also performed by the Grønnesby and Borgan calibration test.^[@b21]^ The incremental effects of addition of PTX3 to PF5 and BNP levels to predict future cardiovascular events were evaluated using the net classification index (NRI), as previously described.^[@b22]^ Patients were stratified into 1 of 3 risk categories based on PF5 and BNP levels measured during the mean 30‐month follow‐up period: low risk (0% to \<10%), intermediate risk (10% to 20%), or high risk (\>20%). PTX3 was subsequently used to reclassify the risk category for ascertaining whether there would be improvement in the NRI. The NRI was calculated using the following equation: NRI=(\[number of events reclassified as higher−number of events reclassified as lower\]/number of events)−(\[number of nonevents reclassified as lower−number of nonevents reclassified as higher\]/number of nonevents). A *P* value \<0.05 was considered significant. All analyses were performed using SPSS version 19.0J for Windows (IBM Corporation), Stata version 11 (Stata Corporation), and SAS version 9.1.3 (SAS Institute Inc).

Results
=======

Patient Characteristics
-----------------------

[Table 1](#tbl01){ref-type="table"} shows the clinical characteristics of the participating patients. The median PTX3 level was 3.0 ng/mL. Mean age, New York Heart Association class, and BNP levels were higher and mean body mass index, waist circumference and estimated glomerular filtration rate were lower in the high‐PTX3 group (\>3.0 ng/mL) than in the low‐PTX3 group (≤3.0 ng/mL). LVMI values were significantly higher in the high‐PTX3 group than in the low‐PTX3 group, whereas LVEF and E/e' were similar in these 2 groups. Simple linear regression analysis showed a positive and significant correlation between Ln(PTX3) and Ln(BNP) (*r*=0.295, *P*\<0.001) ([Figure 2](#fig02){ref-type="fig"}A) and a significant but weak positive correlation between Ln(PTX3) and Ln(LVMI) (*r*=0.114, *P*\<0.05) ([Figure 2](#fig02){ref-type="fig"}B). Furthermore, simple linear regression analysis showed a significant but weak positive correlation between Ln(PTX3) and Ln(tumor necrosis factor‐α) (*r*=0.106, *P*\<0.05) but not Ln(hs‐CRP) (*P*=0.11) or Ln(interleukin‐6) (*P*=0.80).

###### 

Demographic and Clinical Characteristics of Patients With HFNEF

                                        All HFNEF Patients (n=360)   PTX3                                              
  ------------------------------------- ---------------------------- ------------------------ ------------------------ ---------
  Age, y                                70.5±9.9                     69.3±9.6                 71.5±10.0                \<0.05
  Sex, male/female                      200/160 (55.6%/44.4%)        107/73 (59.4%/41.6%)     93/87 (51.7%/48.3%)      0.17
  NYHA functional class II--III/IV      259/101                      152/28                   107/73                   \<0.001
  Body mass index, kg/m^2^              24.4±3.5                     25.1±3.5                 23.7±3.5                 \<0.001
  Metabolic syndrome, n (%)             157 (43.6)                   83 (46.1)                74 (41.1)                0.40
  Waist circumference, cm               89.5±9.8                     91.5±10.2                87.7±9.1                 \<0.001
  Current smoking, n (%)                50 (13.9)                    23 (12.8)                27 (15.0)                0.64
  Hypertension, n (%)                   274 (76.1)                   134 (74.4)               140 (77.7)               0.54
  Diabetes mellitus, n (%)              171 (47.5)                   84 (46.7)                87 (48.8)                0.83
  Glucose, mg/dL                        106.2±29.1                   104.7±25.6               107.8±32.2               0.32
  Hemoglobin A1c, %                     6.41±1.04                    6.37±0.90                6.46±1.18                0.42
  Atrial fibrillation, n (%)            63 (17.5)                    26 (14.4)                37 (20.6)                0.17
  CAD, n (%)                            240 (66.7)                   124 (68.9)               116 (65.2)               0.50
  HF hospitalization history, n (%)     42 (11.7)                    16 (8.9)                 26 (14.4)                0.14
  Dyslipidemia, n (%)                   181 (50.3)                   121 (67.2)               60 (60.0)                0.19
  Total cholesterol, mg/dL              169.6±31.5                   168.0±28.7               170.4±34.8               0.45
  HDL cholesterol, mg/dL                51.5±13.3                    50.7±12.6                52.3±13.9                0.23
  Triglycerides, mg/dL                  111.7±48.1                   114.5±41.6               108.9±53.9               0.27
  LDL cholesterol, mg/dL                98.0±26.2                    97.1±24.7                98.9±27.7                0.50
  Estimated GFR, mL/min per 1.73 m^2^   63.3±17.4                    65.1±17.2                61.5±17.5                \<0.05
  Inflammatory markers                                                                                                 
  PTX3, ng/mL                           3.00 (1.80 to 3.85)          1.80 (1.44 to 2.29)      3.85 (3.22 to 4.76)      \<0.001
  Hs‐CRP, mg/L                          0.80 (0.40 to 1.75)          0.70 (0.30 to 1.60)      0.85 (0.40 to 2.00)      0.09
  TNF‐α, pg/mL                          1.60 (1.13 to 2.34)          1.55 (1.13 to 2.30)      1.66 (1.15 to 2.37)      0.48
  IL‐6, pg/mL                           1.59 (1.03 to 2.46)          1.56 (1.06 to 2.18)      1.64 (1.00 to 2.85)      0.49
  BNP, pg/mL                            85.4 (30.0 to 174.9)         52.4 (25.4 to 110.5)     122.9 (47.6 to 256.6)    \<0.001
  Echocardiography                                                                                                     
  LVEF, %                               63.2±6.7                     63.3±6.6                 63.1±6.9                 0.73
  E/e'                                  15.5 (12.6 to 18.0)          15.6 (12.9 to 18.1)      15.3 (12.5 to 18.0)      0.58
  LV mass index, g/m^2^                 153.5 (128.0 to 183.4)       147.8 (123.6 to 177.7)   156.5 (131.5 to 187.0)   \<0.05
  Medications                                                                                                          
  Beta blockers, n (%)                  182 (50.6)                   96 (53.3)                86 (47.8)                0.34
  ACE‐Is or ARBs, n (%)                 251 (69.7)                   126 (70.0)               125 (69.4)               0.99
  Ca channel blockers, n (%)            224 (62.2)                   114 (63.3)               110 (61.1)               0.74
  Statins, n (%)                        219 (60.8)                   117 (65.0)               102 (56.7)               0.13
  Aspirin, n (%)                        261 (72.5)                   134 (74.4)               127 (60.6)               0.20
  Diuretics, n (%)                      80 (22.2)                    33 (18.6)                47 (26.1)                0.10
  Spironolactone, n (%)                 39 (10.8)                    15 (8.3)                 24 (13.3)                0.17

Data are mean±SD, number of patients (%), or median (interquartile range). ACE‐I indicates angiotensin‐converting enzyme inhibitors; ARB, angiotensin II receptor blocker; BNP, B‐type natriuretic peptide; CAD, coronary artery disease; E/e', mitral early diastolic peak flow velocity to tissue Doppler early mitral annular diastolic velocity; GFR, glomerular filtration rate; HDL, high‐density lipoprotein; HF, heart failure; HFNEF, heart failure with normal ejection fraction; hs‐CRP, high‐sensitive C‐reactive protein; IL‐6, interleukin‐6; LDL, low‐density lipoprotein; LV, left ventricle; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PTX3, pentraxin 3; TNF‐α, tumor necrosis factor‐α.

![Relationships between PTX3 and BNP levels and PTX3 levels and LVMI. Simple linear regression analysis shows a positive and significant correlation between (A) Ln(PTX3) and Ln(BNP) (*r*=0.295, *P*\<0.001) and (B) a significant but weak positive correlation between Ln(PTX3) and Ln(LVMI) (*r*=0.114, *P*\<0.05). BNP indicates B‐type natriuretic peptide; LVMI; left ventricular mass index; PTX3, pentraxin 3.](jah3-3-e000928-g2){#fig02}

Cardiovascular Events
---------------------

Cardiovascular events were analyzed over time in 360 patients with HFNEF. The mean follow‐up period was 30 months (range: 1 to 59 months). During this time, 106 of these patients experienced cardiovascular events, including cardiovascular death (n=9), nonfatal MI (n=4), unstable angina pectoris (n=13), ischemic stroke (n=9), hospitalization for HF decompensation (n=41), and coronary revascularization (n=30). The frequency of cardiovascular events was significantly higher in the high‐PTX3 group (n=75) than in the low‐PTX3 group (n=31, *P*\<0.001) ([Table 2](#tbl02){ref-type="table"}). HF‐related cardiovascular events, including cardiovascular death and hospitalization for HF decompensation, were significantly higher in the high‐PTX3 group (n=41) than in the low‐PTX3 group (n=9) (*P*\<0.001) ([Table 2](#tbl02){ref-type="table"}). Kaplan‐Meier analysis showed that the probability of cardiovascular events was also significantly higher in the high‐PTX3 group than in the low‐PTX3 group (*P*\<0.001, log‐rank test) ([Figure 3](#fig03){ref-type="fig"}A).

###### 

Cardiovascular Events in HFNEF Patients With Low and High Plasma PTX3 Levels

  ------------------------------------------------------------------------------------------------------
                                          Low‐PTX3 Group (n=180)   High‐PTX3 Group (n=180)   *P* Value
  --------------------------------------- ------------------------ ------------------------- -----------
  Total cardiovascular events             31 (17.2%)\              75 (41.7%)\               \<0.001
                                          \[17.5%\]                \[42.4%\]                 

  Cardiovascular death                    1 (0.6%)\                8 (4.4%)\                 \<0.05
                                          \[0.4%\]                 \[2.5%\]                  

  Nonfatal myocardial infarction          2 (1.1%)\                2 (1.1%)\                 0.99
                                          \[0.1%\]                 \[0.1%\]                  

  Unstable angina                         4 (2.2%)\                9 (5.0%)\                 0.26
                                          \[2.0%\]                 \[4.7%\]                  

  Ischemic stroke                         2 (1.1%)\                7 (3.9%)\                 0.17
                                          \[0.9%\]                 \[3.6%\]                  

  Hospitalization for HF decompensation   8 (4.4%)\                33 (18.3%)\               \<0.001
                                          \[4.5%\]                 \[18.2%\]                 

  Coronary revascularization              14 (7.8%)\               16 (8.9%)\                0.85
                                          \[7.4%\]                 \[8.6%\]                  

  HF‐related cardiovascular events        9 (5.0%)\                41 (22.8%)\               \<0.001
                                          \[5.0%\]                 \[21.9%\]                 
  ------------------------------------------------------------------------------------------------------

Differences between the groups were assessed by the log‐rank test. Lower line in the angled bracket: Age‐ and sex‐adjusted event rates. HF indicates heart failure; HF‐related cardiovascular events, cardiovascular death and hospitalization for HF decompensation; HFNEF, heart failure with normal left ventricular ejection fraction; PTX3, pentraxin 3.

![Kaplan‐Meier analysis for the probability of cardiovascular events. Patients with (A) high PTX3 levels and low PTX3 levels, (B) subgroups of patients with high and low PTX3 levels plus BNP, and (C) subgroups of New York Heart Association class II patients with high and low PTX3 levels are shown. BNP indicates B‐type natriuretic peptide; PTX3, pentraxin 3.](jah3-3-e000928-g3){#fig03}

The combination of PTX3 and BNP levels led to identification of subgroups (n=116, high‐PTX3 and BNP group; n=64, high‐PTX3 and low‐BNP group; n=64, low‐PTX3 and high‐BNP group; and n=116, low‐PTX3 and BNP group) with significantly different probabilities of cardiovascular events (*P*\<0.001, log‐rank test) ([Figure 3](#fig03){ref-type="fig"}B). In the low‐BNP (*P*=0.02) and high‐BNP (*P*\<0.01) groups, the probability of cardiovascular events was significantly higher in those with high PTX3 levels than in those with low PTX3 levels. Even among patients with mild HF symptoms (New York Heart Association class II), the outcomes were poorer in patients with high PTX3 levels than in those with low PTX3 levels (*P*\<0.001, log‐rank test) ([Figure 3](#fig03){ref-type="fig"}C).

Cox Proportional Hazards Analysis and C‐Statistics for Cardiovascular Events
----------------------------------------------------------------------------

The results of univariate and multivariable Cox proportional hazards analyses for cardiovascular events are shown in Tables [3](#tbl03){ref-type="table"} and [4](#tbl04){ref-type="table"}. Multivariable Cox proportional hazards analysis identified PTX3 (hazard ratio \[HR\]: 1.16; 95% CI: 1.05 to 1.27; *P*\<0.01), high‐density lipoprotein cholesterol (HR: 0.99; 95% CI: 0.97 to 0.99; *P*\<0.05), LVMI (HR: 1.03; 95% CI: 1.05 to 1.27), and BNP (HR: 1.08; 95% CI: 1.03 to 1.14; *P*\<0.001) as predictors of future cardiovascular events after adjustment for significant factors that were identified by univariate analysis ([Table 3](#tbl03){ref-type="table"}). Using the forced inclusion model, which evaluated levels of inflammatory markers and BNP (model 1) in multivariable Cox hazards analysis, PTX3, but not hs‐CRP, significantly predicted cardiovascular events (HR: 1.17; 95% CI: 1.07 to 1.28; *P*\<0.001). In the forced inclusion model, which included PF5 and BNP, PTX3 significantly predicted cardiovascular events (model 2: HR: 1.16; 95% CI: 1.05 to 1.27; *P*\<0.01; model 4: HR: 1.16; 95% CI: 1.06 to 1.27; *P*\<0.01) ([Table 4](#tbl04){ref-type="table"}). Furthermore, multivariable Cox proportional hazards analysis identified PTX3 (HR: 1.16; 95% CI: 1.01 to 1.35; *P*\<0.05) and BNP (HR: 1.21; 95% CI: 1.11 to 1.31; *P*\<0.001) as predictors of future HF‐related cardiovascular events, including cardiovascular death and hospitalization for HF decompensation, after adjustment for significant factors identified by univariate analysis. We classified patients with HFNEF into 4 groups according to the levels of Ln(PTX3): first quartile (\<0.59, PTX3: \<1.80 ng/mL), second quartile (0.59 to 1.10, PTX3: 1.80 to 3.00 ng/mL), third quartile (1.10 to 1.35, PTX3: 3.00 to 3.85 ng/mL), and fourth quartile (\>1.35, PTX3: \>3.85 ng/mL); the relative risk of total cardiovascular events was 1 (reference), 1.36, 2.71 (*P*\<0.001 versus the reference), and 3.17 (*P*\<0.001 versus the reference), respectively. The log‐transformation values of PTX3 demonstrated a linear association with the occurrence of cardiovascular events in patients with HFNEF (*r*=0.965, *P*=0.03).

###### 

Cox Proportional Hazards Analysis of Factors That Were Predictive of Future Cardiovascular Events in Patients With HFNEF After Adjustment for Significant Factors Identified by Univariate Analysis

  Factor                                 Univariate            Multivariable                         
  -------------------------------------- --------------------- --------------- --------------------- ---------
  Age, y                                 1.04 (0.98 to 1.03)   0.20                                  
  Sex, male                              1.31 (0.88 to 1.93)   0.18                                  
  NYHA functional class III or IV, yes   1.97 (1.34 to 2.91)   \<0.001         1.08 (0.69 to 1.69)   0.74
  Body mass index, kg/m^2^               0.96 (0.91 to 1.02)   0.55                                  
  Metabolic syndrome, yes                1.01 (0.69 to 1.49)   0.95                                  
  Waist circumference, cm                1.00 (0.98 to 1.02)   0.72                                  
  Current smoking                        1.40 (0.85 to 2.30)   0.19                                  
  Hypertension, yes                      0.93 (0.61 to 1.45)   0.77                                  
  Diabetes mellitus, yes                 1.45 (0.99 to 2.13)   0.056                                 
  Glucose, per mg/dL                     1.00 (0.99 to 1.01)   0.08                                  
  Hemoglobin A1c, per%                   1.17 (0.98 to 1.38)   0.09                                  
  Atrial fibrillation, yes               1.76 (1.13 to 2.74)   \<0.05          1.19 (0.75 to 1.90)   0.46
  CAD, yes                               1.47 (0.95 to 2.27)   0.08                                  
  HF hospitalization history, yes        1.16 (0.66 to 2.04)   0.60                                  
  Dyslipidemia, yes                      1.04 (0.70 to 1.55)   0.85                                  
  Total cholesterol, mg/dL               0.99 (0.98 to 1.01)   0.07                                  
  HDL cholesterol, mg/dL                 0.98 (0.97 to 0.99)   \<0.05          0.99 (0.97 to 0.99)   \<0.05
  Triglycerides, mg/dL                   1.00 (0.99 to 1.01)   0.62                                  
  LDL cholesterol, mg/dL                 0.99 (0.98 to 1.01)   0.10                                  
  Ln(PTX 3), 0.1                         1.23 (1.13 to 1.34)   \<0.001         1.16 (1.05 to 1.27)   \<0.01
  Ln(hs‐CRP), 0.1                        0.99 (0.95 to 1.02)   0.44                                  
  Ln(TNF‐α), 0.1                         1.01 (0.95 to 1.06)   0.87                                  
  Ln(IL‐6), 0.1                          1.03 (0.97 to 1.08)   0.34                                  
  Ln(BNP), 0.1                           1.12 (1.07 to 1.16)   \<0.001         1.08 (1.03 to 1.14)   \<0.001
  Estimated GFR, mL/min per 1.73 m^2^    0.98 (0.97 to 0.99)   \<0.05          1.00 (0.99 to 1.01)   0.86
  LVEF, %                                0.98 (0.95 to 1.01)   0.10                                  
  Ln(E/e'), 0.1                          0.98 (0.92 to 1.05)   0.57                                  
  Ln(LV mass index), 0.1                 1.08 (1.01 to 1.16)   \<0.05          1.03 (1.05 to 1.27)   \<0.01

BNP indicates B‐type natriuretic peptide; CAD, coronary artery disease; E/e', mitral early diastolic peak flow velocity to tissue Doppler early mitral annular diastolic velocity; GFR, glomerular filtration rate; HDL, high‐density lipoprotein; HF, heart failure; HFNEF, heart failure with normal ejection fraction; HR, hazard ratio; hs‐CRP, high‐sensitivity C‐reactive protein; IL‐6, interleukin‐6; LDL, low‐density lipoprotein; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PTX3, pentraxin 3; TNF‐α, tumor necrosis factor‐α.

###### 

Cox Proportional Hazards Analysis of Factors That Were Associated With Future Cardiovascular Events in HFNEF Patients Using Forced Inclusion Models

  Factor                                       Model 1               Model 2   Model 3               Model 4                                                         
  -------------------------------------------- --------------------- --------- --------------------- --------- --------------------- --------- --------------------- ---------
  Age, y                                                                       1.00 (0.98 to 1.02)   0.95      1.01 (0.99 to 1.03)   0.57      1.00 (0.98 to 1.02)   0.98
  NYHA functional class III or IV, yes                                         1.12 (0.72 to 1.75)   0.63      1.27 (0.81 to 1.98)   0.30      1.12 (0.73 to 1.77)   0.58
  Diabetes mellitus, yes                                                       1.52 (1.04 to 2.24)   \<0.05    1.50 (1.06 to 2.30)   \<0.05    1.50 (1.02 to 2.21)   \<0.05
  History of HF‐related hospitalization, yes                                   1.60 (0.88 to 2.89)   0.12      1.67 (0.92 to 3.04)   0.10      1.65 (0.91 to 3.00)   0.10
  LVEF, %                                                                      0.99 (0.95 to 1.02)   0.38      0.99 (0.96 to 1.02)   0.39      0.99 (0.96 to 1.02)   0.38
  Ln(PTX3), 0.1                                1.17 (1.07 to 1.28)   \<0.001   1.16 (1.05 to 1.27)   \<0.01                                    1.16 (1.06 to 1.27)   \<0.01
  Ln(hs‐CRP), 0.1                              0.98 (0.94 to 1.02)   0.26                                      0.99 (0.95 to 1.02)   0.40      0.98 (0.94 to 1.02)   0.22
  Ln(TNF‐α), 0.1                               0.99 (0.94 to 1.04)   0.67                                                                                            
  Ln(IL‐6), 0.1                                1.00 (0.95 to 1.06)   0.84                                                                                            
  Ln(BNP), 0.1                                 1.09 (1.05 to 1.14)   \<0.001   1.10 (1.05 to 1.27)   \<0.01    1.11 (1.06 to 1.17)   \<0.001   1.10 (1.04 to 1.15)   \<0.001

BNP indicates B‐type natriuretic peptide; CI, confidence interval; HF, heart failure; HFNEF, heart failure with normal ejection fraction; HR, hazard ratio; hs‐CRP, high‐sensitive C‐reactive protein; IL‐6, interleukin‐6; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PTX3, pentraxin 3; TNF‐α, tumor necrosis factor‐α.

We also estimated the C‐statistics of PF5 alone. Separate incorporation of PTX3 and BNP into PF5 increased the C‐statistics for the prediction of future cardiovascular events from 0.617 for PF5 alone to 0.656 for PF5 plus PTX3 and PF5 plus BNP ([Table 5](#tbl05){ref-type="table"}). Moreover, incorporation of PTX3 and BNP into PF5 increased the C‐statistics to 0.683 (*P*\<0.05). In addition, the PF5 plus BNP plus PTX3 model performed better than the PF5 plus BNP model (C‐statistics: 0.683 versus 0.656). The Schoenfeld test indicated that the proportional hazards assumptions were appropriate (*P*=0.46). We also confirmed good calibration for the analysis by Grønnesby and Borgan statistics (*P*=0.19).

###### 

C‐Statistics for Cox Proportional Hazards Analysis Predicting Future Cardiovascular Events in Patients With Heart Failure With Normal Ejection Fraction

  Variable       C‐Statistic   95% CI           Increment in C‐Statistic
  -------------- ------------- ---------------- --------------------------
  PF5            0.617         0.555 to 0.681   
  PF5+PTX3       0.656         0.594 to 0.718   0.039
  PF5+BNP        0.656         0.598 to 0.714   
  PF5+BNP+PTX3   0.683         0.624 to 0.742   0.027

BNP indicates B‐type natriuretic peptide; PF5, the 5 factors identified in the I‐PRESERVE study^[@b10]^ as prognostic in patients with heart failure with normal ejection fraction (age, presence of diabetes mellitus, previous hospitalization for heart failure, New York Heart Association classification, and left ventricular ejection fraction); PTX3, pentraxin 3.

Net Reclassification Index
--------------------------

We reclassified the risk of PF5 and BNP for patients with HFNEF. The NRI was significant after PTX3 was included: 12.2% for patients without cardiovascular events, 0% for those with cardiovascular events, and 12.2% overall (*P*\<0.01) ([Table 6](#tbl06){ref-type="table"}).

###### 

Reclassification of the Risk of PF5 and BNP for Cardiovascular Events After the Addition of PTX3

  Original Risk Category                   Reclassification        
  ---------------------------------------- ------------------ ---- -----
  Patients without cardiovascular events                           
  PF5+BNP low risk                         0                  1    0
  PF5+BNP intermediate risk                4                  59   12
  PF5+BNP high risk                        0                  40   138
  Patients with cardiovascular events                              
  PF5+BNP low risk                         0                  0    0
  PF5+BNP intermediate risk                0                  10   4
  PF5+BNP high risk                        0                  4    88

BNP indicates B‐type natriuretic peptide; PF5, the 5 factors identified in the I‐PRESERVE study^[@b10]^ as prognostic in patients with heart failure with normal ejection fraction (age, presence of diabetes mellitus, previous hospitalization for heart failure, New York Heart Association classification, and left ventricular ejection fraction); PTX3, pentraxin 3.

Discussion
==========

To the best of our knowledge, this report is the first to show a significant association between plasma levels of PTX3, a marker of inflammation, and adverse cardiovascular outcomes in patients with HFNEF. High plasma PTX3 levels can significantly predict future cardiovascular events in HFNEF patients. The addition of high PTX3 levels to the PF5 and BNP levels, which were previously found to be prognostic in patients with HFNEF, improved their risk stratification, as indicated by a substantial increase in the C‐statistics and significance of NRI.

Activation of the inflammatory process is important in the pathogenesis of HF and in adverse prognosis of patients with this condition. Several studies have investigated the role of inflammation as a therapeutic target, although initial trials had limited success.^[@b23]^ Consequently, specific anti‐inflammatory approaches for the different types and stages of HF (ie, HFNEF and HFREF) remain a priority, as does a better understanding of the mechanisms underlying HF‐related inflammation. The established inflammatory marker hs‐CRP is an independent predictor of morbidity and mortality in patients with HF.^[@b24]--[@b26]^ Elevated CRP levels predict hospitalization of HF patients, although the association between CRP and HF events is no longer significant after adjustment for the presence of LV diastolic dysfunction.^[@b27]^ Consequently, the relationships between inflammatory markers and the prognosis of patients with HFNEF remain unclear. Myocardial remodeling differs in HFNEF and HFREF.^[@b28]^ In HFREF, remodeling is driven by the loss of cardiomyocytes, whereas in HFNEF, a systemic inflammatory state induces oxidative stress in the coronary microvascular endothelium, which drives myocardial dysfunction and remodeling.^[@b28]^ Other studies have shown that serum levels of inflammatory cytokines are high in patients with HFNEF^[@b29]^ and that interleukin‐16, a cytokine considered an important mediator in inflammation, promotes cardiac fibrosis and myocardial stiffening in HFNEF.^[@b30]^ Consequently, investigating the relationships between inflammatory markers and prognosis in HFNEF is important. We observed a significant correlation between plasma levels of PTX3, a novel inflammatory maker, and future cardiovascular events in patients with HFNEF. Furthermore, considerable evidence suggests that PTX3 may better reflect local inflammatory status in tissues than does liver‐derived CRP.^[@b6]^ We previously reported that PTX3 was partly produced in the coronary circulation in patients with HFNEF.^[@b7]^ These results suggest that PTX3, rather than CRP, reflects vascular and cardiac inflammation in patients with HFNEF and might be a cardiovascular biomarker for the assessment and management of HF. In the present study, we showed that increased inflammation as assessed by PTX3 measurement was significantly associated with poor prognosis for HFNEF patients by multivariable Cox hazards analysis. Furthermore, the addition of 2 biomarkers---PTX3 as an inflammation maker and BNP as a myocardial stress marker---to the previously established prognostic factors in the I‐PRESERVE study^[@b10]^ of HFNEF patients improved their risk stratification performance, as indicated by an increase in the C‐statistics. These results suggest the possible relative merits of these 2 biomarkers for future risk management in HFNEF. In NRI analyses, the addition of PTX3 was able to provide a more appropriate risk assessment in patients who were evaluated as having a high risk state by previously described HFNEF prognostic factors (PF5 plus BNP) in patients without cardiovascular events. Furthermore, the addition of PTX3 never resulted in a worse risk classification in patients with cardiovascular events. Consequently, the significance of NRI was shown by incorporating PTX3 into the new risk‐assessment model.

The site of PTX3 production in patients with HFNEF remains unclear. Under normal physiological conditions, PTX3 mRNA is not expressed in the heart.^[@b31]^ Under pathological conditions, PTX3 is expressed in atherosclerotic lesions,^[@b32]^ adipose tissue,^[@b33]^ and the heart with acute and sub‐acute‐phase HF^[@b34]^; however, the types of cells that express PTX3 in failing hearts of patients with HFNEF and chronic HF have not been determined. HFNEF may result from the accumulation of extracellular matrix material within myocardial fibrosis.^[@b35]--[@b36]^ Accumulation of the extracellular matrix (ie, fibrosis) may also be pathophysiologically important in progression of the HFNEF disease process and be a contributor to subsequent events.^[@b37]^ HFNEF may also be caused by structural and molecular abnormalities of the cardiovascular system, including cardiac and noncardiac factors, such as those associated with vascular functions.^[@b38]^ We recently demonstrated significant involvement of endothelial dysfunction in the prognosis of patients with HFNEF, suggesting that improvement in endothelial function could be a potential therapeutic target in patients with HFNEF.^[@b39]^ PTX3 is produced by fibrous tissues and endothelial cells in response to inflammatory stimuli^[@b5]^ and is considered an important marker of vascular pathology.^[@b40]^ In patients with acute MI and infectious myocarditis, PTX3 is produced by macrophages, endothelial cells, and, to a lesser extent, myocardiocytes and is localized in the interstitium.^[@b34]^ The interstitial localization of PTX3 in human failing hearts suggests that PTX3 is produced locally by fibroblasts in the cardiac interstitium. Consequently, in patients with HFNEF, PTX3 might be produced by myocardial fibroblasts and/or endothelial cells rather than in subclinical atherosclerotic lesions in patients with HFNEF. We found that the frequency of HF‐related cardiovascular events, including cardiovascular death and hospitalization for HF decompensation, was significantly higher in patients with high PTX3 levels than in those with low PTX3 levels. This finding suggests that PTX3 is more predictive of future HF‐related cardiovascular events than of vascular events in patients with HFNEF.

We used the median value of PTX3 (3.0 ng/mL) as the cutoff point in the present study. Several studies have investigated the association between PTX3 values and HF. Suzuki et al demonstrated that the median value of PTX3 was 3.7 ng/mL in patients with HFREF and split the patients into 2 groups: those above and those below 4.0 ng/mL.^[@b8]^ In this study, patients with HFREF were targeted, and it has already been demonstrated that patients with HFREF have higher inflammatory activity than those with HFNEF. We previously demonstrated that the 75% range value of PTX3 was 2.90 ng/mL in non‐HF patients with risk factors (hypertension, 67.8%; diabetes mellitus, 37.4%; dyslipidemia, 57.1%; and coronary artery disease, 55.0%).^[@b7]^ Furthermore, Inoue et al showed that PTX3 levels were \<2.28 ng/mL in healthy volunteers.^[@b41]^ In previous studies of cardiovascular events in stable patients with coronary risk factors, the cutoff points of PTX3 were 2.83^[@b42]^ and 3.24 ng/mL.^[@b43]^ Thus, we consider that the median value of 3.0 ng/mL for PTX3 was a clinically meaningful cutoff point in our study.

The present study has several limitations. First, our study included only a relatively small number of patients in a single center. Second, the population of this study was relatively young and predominantly male; had a low prevalence of atrial fibrillation, a higher frequency of mild HF, relatively lower BNP levels; and had less frequent use of diuretics. Because our institution is an educational hospital and the design was a single‐center study in Japan, the recruited patients with HFNEF might have had differences in characteristics compared with those in Western studies. Consequently, a large, multiracial, multicenter study is required to confirm our results. Third, the pathogenetic role of high PTX3 levels in HFNEF remains unclear. Recent studies in mouse models have shown that PTX3 has a cardioprotective effect,^[@b44]--[@b45]^ suggesting that PTX3 might protect the cardiovascular system by modulating the immune--inflammatory balance. Further in vivo and in vitro experiments are required to determine the exact role of high PTX3 levels in HFNEF.

Despite these limitations, our study provided the first evidence for the prognostic significance of PTX3 in HFNEF. A large‐scale multicenter trial is warranted to further examine the pathological role and clinical significance of PTX3 in HFNEF.

Conclusion
==========

High plasma PTX3 levels, but not other inflammatory markers including hs‐CRP, are significantly correlated with future cardiovascular events in patients with HFNEF. Determination of PTX3 levels may provide incremental prognostic information in patients with HFNEF.
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